Analysis of phase II and phase III clinical trial terminations from 2013 to 2023 www.nature.com/articles/d41... This new article analyses trials terminated before completion by sponsors, highlighting strategy/business reasons as a driver of an overall increase in annual terminations

Trends in target novelty in oncology R&D nature.com/articles/d41... This new article analyses the novelty of targets being investigated in oncology drug R&D, and reveals that the majority of late-stage oncology drugs do not have a novel target

Betting on β-catenin inhibitors in oncology www.nature.com/articles/d41... The WNT–β-catenin pathway is often overactive in cancer. Can emerging drugs — including stabilized peptides, condensate modulators and degraders — safely and effectively tamp it back down?

How multispecific molecules are transforming pharmacotherapy rdcu.be/eUp4U nature.com/articles/s41... This article in the December issue discusses how drugs designed to engage two or more entities are overcoming development barriers such as toxicity and redundancy

For readers interested in GLP-1-based therapies for metabolic diseases and beyond, here's a recent review rdcu.be/eT39F nature.com/articles/s41...

Top product forecasts for 2026 nature.com/articles/d41... The top ten best-selling drugs are projected to generate sales of US$198 billion in 2026, driven by the GLP-1-based products for metabolic diseases. Find out more in this new article.

For readers interested in genome editing therapeutics, this Review in the December issue discusses progress in the application of CRISPR-based genome editing to treat inherited blood disorders such as sickle cell disease rdcu.be/eTR9i www.nature.com/articles/s41...

For readers interested in drugs targeting TNF superfamily members such as APRIL and their receptors, here's a comprehensive review rdcu.be/eTG0e www.nature.com/articles/s41...

First-in-class APRIL inhibitor secures approval for rare kidney disease www.nature.com/articles/d41...

For readers interested in drug repurposing, this article overviews computational approaches to drug repurposing and evaluates available in silico resources rdcu.be/eSY57 www.nature.com/articles/s41...

Stimulating medicines repurposing in the EU: a pilot project nature.com/articles/d41... This new article discusses a project testing a framework to support not-for-profit organizations and academia to generate the evidence needed for a regulatory submission of a repurposed drug

The FDA recently approved the 100th small-molecule kinase inhibitor, a quarter of a century on from the landmark approval of imatinib. Read about progress and the key trends in the field in this article in the December issue www.nature.com/articles/d41...

Our December issue is live! Read about how multispecific molecules are transforming pharmacotherapy, CRISPR-based genome editing for blood disorders, advances in the treatment of lupus, progress with small-molecule kinase inhibitors and more here www.nature.com/nrd/volumes/...

Chemical modifications can improve the stability, efficiency and specificity of RNA therapeutics, while reducing their immunogenicity - find out more in this review rdcu.be/eSyD6 www.nature.com/articles/s41...

Excellent review on induced proximity-based therapeutic modalities! Thank you, @dannomura.bsky.social, for featuring our work in the "Targeted Protein Subcellular Localization" section and in Fig. 8!

Happy to share this landscape analysis from Novartis #GlobalHealth colleagues published in @natrevdrugdiscov.nature.com exploring 2 decades of data on approvals, clinical dev. trends, and modalities across 40 diseases with major GH implications. www.nature.com/articles/d41...

For readers interested in drug development for malaria, here's a review covering strategies to combat drug resistance in malaria, HIV and tuberculosis rdcu.be/eRVfv www.nature.com/articles/s41...

Novel antimalarial passes key phase III test www.nature.com/articles/d41... Novartis’s ganaplacide plus lumefantrine (GanLum) is as effective as standard-of-care artemether plus lumefantrine (Coartem) for acute, uncomplicated malaria due to P. falciparum

Epigenetic editing: from concept to clinic rdcu.be/eRJBO www.nature.com/articles/s41... Epigenetic editing aims to reprogramme gene expression by rewriting epigenetic signatures, without editing of the genome. Find out about progress in the field in this new Review

Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action www.nature.com/articles/d41... This new Comment article presents recommendations to address barriers to the implementation of pharmacogenomics

For readers interested in the frontiers of cell therapies for cancer, here's a review on in vivo CAR-T cells, which could address some of the limitations of the approved ex vivo therapies rdcu.be/eQ9Ho www.nature.com/articles/s41...

Accelerating progress in immune cell therapy for solid tumours www.nature.com/articles/d41... This Comment article discusses how collaborative translational research and adaptive clinical trial design are needed to advance novel T cell therapies towards achieving cures in solid tumours

Targeting the Hippo pathway in cancer rdcu.be/eQL6l nature.com/articles/s41... This Review in the November issue discusses Hippo pathway-targeted therapies, particularly those that target TEAD proteins and their interaction with the YAP/TAZ transcription co-activators

For readers interested in therapeutic strategies based on inducing proximity between proteins, such as Halda's RIPTACs, here's a review on the field www.nature.com/articles/s41... rdcu.be/eQzXF and a news story on RIPTACs www.nature.com/articles/d41...

Johnson & Johnson said Monday it will purchase Halda Therapeutics and its experimental prostate cancer drugs for $3.05 billion. www.statnews.com/2025/11/17/h...

FDA approves 100th small-molecule kinase inhibitor www.nature.com/articles/d41... From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes

For readers interested in GLP-1-based therapies for diabetes, obesity and beyond, here's a recent review rdcu.be/ePXoK www.nature.com/articles/s41...

Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot nature.com/articles/d41... The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab

New from the @hansclevers.bsky.social group Drug screening and human organoids @natrevdrugdiscov.nature.com www.nature.com/articles/s41...

Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges www.nature.com/articles/s41... rdcu.be/ePz9n This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges

This article in the November issue discusses the changing landscape of medicinal chemistry optimization based on analysis of sets of hits, leads and drug candidates, which reveals shifts in key physicochemical properties rdcu.be/ePoB9 www.nature.com/articles/s41...

For readers interested in therapies that harness regulatory T cells to treat disease, here's a review on this topic rdcu.be/ePb76 www.nature.com/articles/s41... and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...

“It’s about time”: Tregs win the Nobel prize www.nature.com/articles/d41... Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview

For readers interested in bispecific antibodies as cancer therapies, here's a review rdcu.be/eOONr www.nature.com/articles/s41...

Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d41... Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development

Cancer cell therapies: global clinical trial trends and emerging directions www.nature.com/articles/d41... This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field

For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges rdcu.be/eOpGH www.nature.com/articles/s41...

FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41... Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade

Induced proximity-based therapeutic modalities nature.com/articles/s41... rdcu.be/eOfBH This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more

For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review rdcu.be/eN4SK www.nature.com/articles/s41...

Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061

Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...

For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review rdcu.be/eNiYv www.nature.com/articles/s41...

In its second pipeline-expanding deal in the space of 24 hours, #GSK has licensed rights to a drug for chronic obstructive pulmonary disease (#COPD) from US biotech #Empirico for $85 million upfront. pharmaphorum.com/news/gsk-str...

For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review rdcu.be/eNiHj www.nature.com/articles/s41...

Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety www.nature.com/articles/s41... rdcu.be/eM8hs This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them

For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field rdcu.be/eMpeO nature.com/articles/s41...

Trends in gene therapy delivery technologies nature.com/articles/d41... This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery

Join researchers, biotech innovators, and pharma leaders in Boston this December for Cracking the Code: Nucleic Acid Medicines Coming of Age. Explore how advances in RNA and DNA therapeutics are shaping the next generation of medicine. go.nature.com/4nbCcaK 🧬#STEMconference

Intrinsically disordered proteins are frequently dysregulated in disease, but have traditionally been considered 'undruggable'. This Review in the October issue discusses experimental and computational approaches to conquer this barrier in drug discovery rdcu.be/eMbXh www.nature.com/articles/s41...